{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T02:19:04Z","timestamp":1775009944104,"version":"3.50.1"},"reference-count":41,"publisher":"Bentham Science Publishers Ltd.","issue":"8","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2019,6,3]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Nowadays, tuberculosis (TB) is an important global public health problem, being responsible\nfor millions of TB-related deaths worldwide. Due to the increased number of cases and resistance of\nMycobacterium tuberculosis to all drugs used for the treatment of this disease, we desperately need new\ndrugs and strategies that could reduce treatment time with fewer side effects, reduced cost and highly\nactive drugs against resistant strains and latent disease. Considering that, 4H-1,3-benzothiazin-4-one is a\npromising class of antimycobacterial agents in special against TB-resistant strains being the aim of this\nreview the discussion of different aspects of this chemical class such as synthesis, mechanism of action,\nmedicinal chemistry and combination with other drugs.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568026619666190305130809","type":"journal-article","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T10:25:23Z","timestamp":1551781523000},"page":"567-578","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["4H-1,3-Benzothiazin-4-one a Promising Class Against MDR\/XDR-TB"],"prefix":"10.2174","volume":"19","author":[{"given":"Marcus Vinicius Nora","family":"de Souza","sequence":"first","affiliation":[{"name":"FioCruz-Fundacao Oswaldo Cruz, Instituto de Tecnologia em F\u00e1rmacos-Far Manguinhos, Rua Sizenando Nabuco, 100, Manguinhos, 21041-250 Rio de Janeiro-RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thais Cristina Mendon\u00e7a","family":"Nogueira","sequence":"additional","affiliation":[{"name":"FioCruz-Fundacao Oswaldo Cruz, Instituto de Tecnologia em F\u00e1rmacos-Far Manguinhos, Rua Sizenando Nabuco, 100, Manguinhos, 21041-250 Rio de Janeiro-RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"1320","volume":"13","author":"Zhang Y.","year":"2009","unstructured":"Zhang Y, Yew WW.  Mechanisms of drug resistance in","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref=2","author":"","year":"2010","unstructured":".","journal-title":"Multidrug and extensively drug-resistant TB (M\/XDR-TB): 2010 Global Report on Surveillance and response"},{"key":"ref=3","unstructured":"WHO TB drug resistance types.(Accessed at, http:\/\/www.who.int\/ tb\/areas-of-work\/drug-resistant-tb\/types\/en\/"},{"key":"ref=4","author":"","year":"2012","unstructured":".","journal-title":"A WHO consultation on the diagnostic definition and treatment options"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2165\/11538170-000000000-00000","volume":"70","author":"Ginsberg A.M.","year":"2010","unstructured":"Ginsberg AM.  Drugs in development for tuberculosis.","journal-title":"Drugs"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2012.02.033","volume":"51","author":"Villemagne B.","year":"2012","unstructured":"Villemagne B, Crauste C, Flipo M, Baulard AR, D\u00e9prez B, Willand N.  Tuberculosis: The drug development pipeline at a glance.","journal-title":"Eur J Med Chem"},{"key":"ref=7","unstructured":"European Medicines Agency. 2010. (Accessed at. http:\/\/www. ema.europa.eu\/docs\/en_GB\/document_library\/Orphan_designation\/2010\/06\/WC500094022.pdf"},{"key":"ref=8","unstructured":"FDA Application No. 204384. 2012. (Accessed at https:\/\/www. accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/204384Orig1s000 SumR.pdf"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1106753","volume":"307","author":"Andries K.","year":"2005","unstructured":"Andries K, Verhasselt P, Guillemont J, G\u00f6hlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V.  A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.","journal-title":"Science"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1128\/AAC.01676-09","volume":"54","author":"Pasca M.R.","year":"2010","unstructured":"Pasca MR, Degiacomi G, Ribeiro ALDJL, Zara F, De Mori P, Heym B, Mirrione M, Brerra R, Pagani L, Pucillo L, Troupioti P, Makarov V, Cole ST, Riccardi G.  Clinical isolates of  in four European hospitals are uniformly susceptible to benzothiazinones.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=11","unstructured":"Makarov, V.; Cole, S.T.; Moellmann, U. New Benzothiazinone derivatives and their use as antibacterial agents. Germany, WO2007134625A1,, 2007."},{"key":"ref=12","unstructured":"New, T.B. Drugs, Clinical Pipeline. 2018. (Accessed at https:\/\/www.newtbdrugs.org\/pipeline\/clinical"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.1171583","volume":"324","author":"Makarov V.","year":"2009","unstructured":"Makarov V, Manina G, Mikusova K, M\u00f6llmann U, Ryabova O, Saint-Joanis B, Dhar N, Pasca MR, Buroni S, Lucarelli AP, Milano A, De Rossi E, Belanova M, Bobovska A, Dianiskova P, Kordulakova J, Sala C, Fullam E, Schneider P, McKinney JD, Brodin P, Christophe T, Waddell S, Butcher P, Albrethsen J, Rosenkrands I, Brosch R, Nandi V, Bharath S, Gaonkar S, Shandil RK, Balasubramanian V, Balganesh T, Tyagi S, Grosset J, Riccardi G, Cole ST.  Benzothiazinones kill  by blocking arabinan synthesis.","journal-title":"Science"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"13663","DOI":"10.1021\/ja106357w","volume":"132","author":"Trefzer C.","year":"2010","unstructured":"Trefzer C, Rengifo-Gonzalez M, Hinner MJ, Schneider P, Makarov V, Cole ST, Johnsson K.  Benzothiazinones: Prodrugs that covalently modify the decaprenylphosphoryl-\u03b2-D-ribose 2\u2032-epimerase DprE1 of Mycobacterium tuberculosis.","journal-title":"J Am Chem Soc"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.2174\/092986710791959693","volume":"17","author":"Manina G.","year":"2010","unstructured":"Manina G, Pasca MR, Buroni S, De Rossi E, Riccardi G.  Decaprenylphosphoryl-\u03b2-D-ribose 2\u2032-epimerase from  is a magic drug target.","journal-title":"Curr Med Chem"},{"key":"ref=16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004395","volume":"4","author":"Neres J.","year":"2012","unstructured":"Neres J, Pojer F, Molteni E, Chiarelli LR, Dhar N, Boy-R\u00f6ttger S, Buroni S, Fullam E, Degiacomi G, Lucarelli AP, Read RJ, Zanoni G, Edmondson DE, De Rossi E, Pasca MR, McKinney JD, Dyson PJ, Riccardi G, Mattevi A, Cole ST, Binda C.  Structural basis for benzothiazinone-mediated killing of","journal-title":"Sci Transl Med"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"6451","DOI":"10.1128\/AAC.01523-16","volume":"60","author":"Foo C.S.","year":"2016","unstructured":"Foo CS, Lechartier B, Kolly GS, Boy-R\u00f6ttger S, Neres J, Rybniker J, Lupien A, Sala C, Piton J, Cole ST.  Characterization of DprE1-mediated benzothiazinone resistance in","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"13663","DOI":"10.1021\/ja106357w","volume":"132","author":"Trefzer C.","year":"2010","unstructured":"Trefzer C, Rengifo-Gonzalez M, Hinner MJ, Schneider P, Makarov V, Cole ST, Johnsson K.  Benzothiazinones: Prodrugs that covalently modify the decaprenylphosphoryl-\u03b2-D-ribose 2\u2032-epimerase DprE1 of","journal-title":"J Am Chem Soc"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1021\/ja211042r","volume":"134","author":"Trefzer C.","year":"2012","unstructured":"Trefzer C, \u0160kovierov\u00e1 H, Buroni S, Bobovsk\u00e1 A, Nenci S, Molteni E, Pojer F, Pasca MR, Makarov V, Cole ST, Riccardi G, Miku\u0161ov\u00e1 K, Johnsson K.  Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-\u03b2-D-ribofu-ranose 2\u2032-oxidase DprE1.","journal-title":"J Am Chem Soc"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"11354","DOI":"10.1073\/pnas.1205735109","volume":"109","author":"Batt S.M.","year":"2012","unstructured":"Batt SM, Jabeen T, Bhowruth V, Quill L, Lund PA, Eggeling L, Alderwick LJ, F\u00fctterer K, Besra GS.  Structural basis of inhibition of  DprE1 by benzothiazinone inhibitors.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"11354","DOI":"10.1073\/pnas.1205735109","volume":"109","author":"Batt S.M.","year":"2012","unstructured":"Batt SM, Jabeen T, Bhowruth V, Quill L, Lund PA, Eggeling L, Alderwick LJ, F\u00fctterer K, Besra GS.  Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1074\/jbc.M113.522623","volume":"289","author":"Grover S.","year":"2014","unstructured":"Grover S, Alderwick LJ, Mishra AK, Krumbach K, Marienhagen J, Eggeling L, Bhatt A, Besra GS.  Benzothiazinones mediate killing of Corynebacterineae by blocking decaprenyl phosphate recycling involved in cell wall biosynthesis.","journal-title":"J Biol Chem"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.drudis.2016.09.014","volume":"22","author":"Piton J.","year":"2017","unstructured":"Piton J, Foo CS, Cole ST.  Structural studies of  DprE1 interacting with its inhibitors.","journal-title":"Drug Discov Today"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/anie.201609737","volume":"56","author":"Kloss F.","year":"2017","unstructured":"Kloss F, Krchnak V, Krchnakova A, Schieferdecker S, Dreisbach J, Krone V, M\u00f6llmann U, Hoelscher M, Miller MJ.  \n dearomatization of the potent antituberculosis agent BTZ043  meisenheimer complex formation.","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=25","author":"Rudolph A.I.","year":"2014","unstructured":"Rudolph AI.","journal-title":"Antitubercular Benzothiazinones: Synthesis, activity, properties and SAR"},{"key":"ref=26","first-page":"2024","volume":"36","author":"Shanshan L.","year":"2016","unstructured":"Shanshan L, Hailong H, Ning Z, Limin H, Jiayuan L.  Review about the synthesis of 1,3-benzothiazinone derivatives.","journal-title":"Youji Huaxue"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"7940","DOI":"10.1021\/jm3008882","volume":"55","author":"Karoli T.","year":"2012","unstructured":"Karoli T, Becker B, Zuegg J, M\u00f6llmann U, Ramu S, Huang JX, Cooper MA.  Identification of antitubercular benzothiazinone compounds by ligand-based design.","journal-title":"J Med Chem"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1021\/ml500039g","volume":"5","author":"Tiwari R.","year":"2014","unstructured":"Tiwari R, M\u00f6llmann U, Cho S, Franzblau SG, Miller PA, Miller MJ.  Design and syntheses of anti-tuberculosis agents inspired by BTZ043 using a scaffold simplification strategy.","journal-title":"ACS Med Chem Lett"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1021\/ml5003458","volume":"6","author":"Tiwari R.","year":"2014","unstructured":"Tiwari R, Miller PA, Cho S, Franzblau SG, Miller MJ, Miller MJ.  Syntheses and antituberculosis activity of 1,3-Benzothiazinone sulfoxide and sulfone derived from BTZ043.","journal-title":"ACS Med Chem Lett"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1021\/acsmedchemlett.5b00424","volume":"7","author":"Tiwari R.","year":"2016","unstructured":"Tiwari R, Miller PA, Chiarelli LR, Mori G, \u0160arkan M, Cent\u00e1rov\u00e1 I, Cho S, Miku\u0161ov\u00e1 K, Franzblau SG, Oliver AG, Miller MJ.  Design, syntheses, and anti-tb activity of 1,3-benzothiazinone azide and click chemistry products inspired by BTZ043.","journal-title":"ACS Med Chem Lett"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1021\/ml500039g","volume":"5","author":"Tiwari R.","year":"2014","unstructured":"Tiwari R, M\u00f6llmann U, Cho S, Franzblau SG, Miller PA, Miller MJ.  Design and syntheses of anti-tuberculosis agents inspired by BTZ043 using a scaffold simplification strategy.","journal-title":"ACS Med Chem Lett"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.bmcl.2015.02.061","volume":"25","author":"Peng C.T.","year":"2015","unstructured":"Peng CT, Gao C, Wang NY, You XY, Zhang LD, Zhu YX, Xv Y, Zuo WQ, Ran K, Deng HX, Lei Q, Xiao KJ, Yu LT.  Synthesis and antitubercular evaluation of 4-carbonyl piperazine substituted 1,3-benzothiazin-4-one derivatives.","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijmyco.2015.02.002","volume":"4","author":"Chandran M.","year":"2015","unstructured":"Chandran M, Renuka J, Sridevi JP, Pedgaonkar GS, Asmitha V, Yogeeswari P, Sriram D.  Benzothiazinone-piperazine derivatives as efficient Mycobacterium tuberculosis DNA gyrase inhibitors.","journal-title":"Int J Mycobacteriol"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1021\/acsmedchemlett.7b00106","volume":"8","author":"Lv K.","year":"2017","unstructured":"Lv K, You X, Wang B, Wei Z, Chai Y, Wang B, Wang A, Huang G, Liu M, Lu Y.  Identification of better pharmacokinetic benzothiazinone derivatives as new antitubercular agents.","journal-title":"ACS Med Chem Lett"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1039\/C6RA25712G","volume":"7","author":"Zhang R.","year":"2017","unstructured":"Zhang R, Lv K, Wang B, Li L, Wang B, Liu M, Guo H, Wang A, Lu Y.  Design, synthesis and antitubercular evaluation of benzothiazinones containing an oximido or amino nitrogen heterocycle moiety.","journal-title":"RSC Advances"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2018.03.060","volume":"151","author":"Lv K.","year":"2018","unstructured":"Lv K, Tao Z, Liu Q, Yang L, Wang B, Wu S, Wang A, Huang M, Liu M, Lu Y.  Design, synthesis and antitubercular evaluation of benzothiazinones containing a piperidine moiety.","journal-title":"Eur J Med Chem"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"11163","DOI":"10.1039\/C8RA00720A","volume":"8","author":"Lu X.","year":"2018","unstructured":"Lu X, Gao C, Shi Y, Xin T, Rong J, Liu K, Peng C, Wang N, Lei Q, Zhang Y, Yu L, Wei Y.  Identification of a new series of benzothiazinone derivatives with excellent antitubercular activity and improved pharmacokinetic profiles.","journal-title":"RSC Advances"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"e00681","DOI":"10.1128\/AAC.00681-18","volume":"62","author":"Piton J.","year":"2018","unstructured":"Piton J, Vocat A, Lupien A, Foo CS, Riabova O, Makarov V, Cole ST.  Structure-based drug design and characterization of sulfonyl-piperazinebenzothiazinone inhibitors of DprE1 from Mycobacterium tuberculosis.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/emmm.201303575","volume":"6","author":"Makarov V.","year":"2014","unstructured":"Makarov V, Lechartier B, Zhang M, Neres J, van der Sar AM, Raadsen SA, Hartkoorn RC, Ryabova OB, Vocat A, Decosterd LA, Widmer N, Buclin T, Bitter W, Andries K, Pojer F, Dyson PJ, Cole ST.  Towards a new combination therapy for tuberculosis with next generation benzothiazinones.","journal-title":"EMBO Mol Med"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1128\/AAC.01476-12","volume":"56","author":"Lechartier B.","year":"2012","unstructured":"Lechartier B, Hartkoorn RC, Cole ST.  In vitro combination studies of benzothiazinone lead compound BTZ043 against","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1128\/AAC.00395-15","volume":"59","author":"Lechartier B.","year":"2015","unstructured":"Lechartier B, Cole ST.  Mode of action of clofazimine and combination therapy with benzothiazinones against","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/170441","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T15:52:45Z","timestamp":1565279565000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/170441\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,3]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,6,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026619666190305130809","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-04-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}